Investors

Press releases

2018/12/21

First patient with colorectal cancer dosed in the Phase ll study of birinapant in combination with Keytruda®

Read more
2018/12/14

The transformation into a company focused on clinical development of pharmaceuticals has now been completed and Medivir gives a project update

Read more
2018/11/21

Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Read more

Presentations

Quarterly report presentations

Events

2019/01/22

Redeye Fight Cancer Seminar

Read more
2019/02/14

Year End Report 2018

Read more
2019/05/09

Annual General Meeting 2019

Read more

Corporate Governance

Medivir Corporate Governance documention.

Annual General Meeting

Documentation from Medivir's Annual General Meetings.